Product Name: IgM Heavy Chain Antibody [IM373]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC, WB
Applications: Flow Cytometry: 0.5-1 ug/million cellsIF: 0.5-1 ug/mlWB: 0.5-1 ug/mlIHC (Frozen): 0.5-1 ug/ml for 30 minutes at RT (1)Prediluted format : incubate for 30 min at RT (2)The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Recombinant heavy chain of human IgM was used as the immunogen for this antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 51-12-7
Product: MS023
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names:
Accession NO.:
Protein Ino:
Official Symbol: IGHM
Geneid: 3507
Background: This antibody recognizes a protein of 75kDa, identified as the mu heavy chain of human immunoglobulins. It does not cross-react with alpha (IgA), gamma (IgG), epsilon (IgE), or delta (IgD), heavy chains, T-cells, monocytes, granulocytes, or erythrocytes. The antibody is useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin’s lymphomas. The most common feature of these malignancies is the restricted expression of a single heavy chain class. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is clonal and therefore malignant.
PubMed ID:http://aac.asm.org/content/25/5/646.abstract
